USARx offers multiple ways to purchase this medication. Choose the Best option for you!
Note: This document contains side effect information about sodium zirconium cyclosilicate. Some of the dosage forms listed on this page may not apply to the brand name Lokelma.
Applies to sodium zirconium cyclosilicate: oral powder for suspension
Along with its needed effects, sodium zirconium cyclosilicate (the active ingredient contained in Lokelma) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking sodium zirconium cyclosilicate:
Applies to sodium zirconium cyclosilicate: oral powder for reconstitution
The most commonly reported adverse reactions reported during clinical trials included edema and hypokalemia.
Very common (10% or more): Edema (up to 16.1%)
During clinical trials, edema was reported in 4.4% of patients receiving 5 g/day, 5.9% of patients receiving 10 g/day and 16.1% of patients receiving 15 g/day for up to 28 days (placebo 2.4%). In longer-term trials, 8% to 11% of patients receiving doses less than 15 g/day reported edema, generalized edema and peripheral edema.
Common (1% to 10%): Hypokalemia
Frequency not reported: Increase in sodium bicarbonate concentrations
In clinical trials, 4.1% of patients developed hypokalemia which resolved with dose reduction or discontinuation.
Small, dose-dependent increases in sodium bicarbonate occurred with once daily dosing (1.1 mmol/L at 5 g/day; 2.3 mmol/L at 10 g/day; 2.6 mmol/L at 15 g/day; 0.6 mmol/L in placebo). The clinical significance of this is unknown.